Arecor Therapeutics is moving ahead with its next-generation ultra-rapid insulin. It’s in talks for a co-development deal to bring the therapy into next-gen insulin pumps.
Meanwhile, hVIVO has shared positive results from its RSV trial for Japanese pharma giant Shionogi. It used human challenge trials, exposing healthy volunteers to the virus to test the antiviral quickly.
Roquefort Therapeutics is selling its subsidiary Lyramid in a $10.8 million deal with Pleiades Pharma. The sale gives Roquefort a stake in a clinical portfolio led by a seasoned team.
Faron Pharmaceuticals has smashed its fundraising target, raising €12 million instead of the planned €10 million. The money will go towards trials of its cancer drug, bexmarilimab.
EMV Capital portfolio company ProAxsis is also raising cash, pulling in £800,000 to grow its business and support clinical research. The company says it made solid progress last year, strengthening its commercial platform.
Moving to the University of New Mexico, where researchers have made a major discovery about how cancer spreads. Using ANGLE’s Parsortix system, they found tumour cells team up with immune cells, making them harder to detect.
IQ-AI’s Imaging Biometrics has expanded its deal with Blackford Analysis, part of Bayer. More of its AI imaging tools will now be available to hospitals worldwide.
And Ananda Pharma has brought in Andy Rust as a commercial adviser. Rust has 30 years of pharma experience, including senior roles in pain and respiratory medicine.
Follow us and subscribe on Youtube, our social channels and of course on proactiveinvestors.co.uk
